New research indicates that patients who stop using popular GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who end traditional lifestyle plans.
Findings released in a leading medical journal demonstrates that while overweight people can lose a large proportion of their total mass while using the jabs, the weight comes back at an estimated rate of nearly a kilo each month upon discontinuation.
"Users purchasing such drugs must be cognizant of the risk of fast rebound weight gain when the medication ends," warns expert Dr. Susan Jebb.
This pace of recovery suggests a return to starting weight within about one and a half years.
Comparing Approaches
The research, which examined 37 of studies involving over 9,000 of participants, contrasted the results of GLP-1 agonists with older methods.
Researchers emphasize that people who lose weight through dieting generally have a slower weight regain—perhaps 0.1 kg a month—post-intervention.
The Reason for the Quick Rebound
Doctors suggest the mode of action of the jabs explains the amplified rebound.
The injections imitate a natural hormone called GLP-1, which moderates hunger.
"Sustained high doses of GLP-1 levels several times higher than the body's typical production might result in the body to generate a reduced amount of its own natural hormone, and could lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this hormone supplement leads to appetite is no longer kept in check, making binge eating much more probable."
An Ongoing Condition?
Health authorities advise the injections for individuals with weight-linked medical conditions, alongside recommended diet and exercise modifications.
A number of clinicians contend that, due to the high risk of weight regain, the therapy might need to be long-term.
This view is reinforced by drug manufacturers, who note that the results "underscore the long-term nature of excess weight," comparing it to managing diseases like diabetes.
Patient Accounts
People who have stopped the medication explain a intense return of hunger.
"I experienced a switch activating and you become ravenous," described an individual.
This difficulty is worsened if individuals have not developed permanent dietary or behavioural modifications during therapy.
Widespread Use
Survey data indicate that a significant number of adults in the UK have tried these injections in the last 12 months, with desire being substantial.
- Adoption is greater among females than males.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
Finally, clinicians emphasize that while these medications are effective tools for shedding pounds, they are not a magic solution and long-term success relies on integrated behavioural management.
